ArticleEuropean journal of medical research2025
Early acetaminophen use is associated with the reduced mortality risk in patients with sepsis-associated encephalopathy: a retrospective study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Histone Deacetylase Activity Model for the Discovery and Validation of Sepsis Biomarkers.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Blood-brain barrier penetration determines link between beta blockers and reduced mortality in patients with sepsis-associated encephalopathy: A multicenter cohort study and an effect heterogeneity tool.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSepsis-associated encephalopathy (SAE), a severe neurological complication of systemic infection, carries substantial morbidity and mortality risks. This study aims to examine the relationship between early acetaminophen use and survival rates in critically ill SAE patients.
methodsUsing data from the MIMIC-IV database, we conducted a retrospective cohort study on patients with SAE, stratified by acetaminophen exposure within 48 h of ICU admission. Among the 4111 eligible patients (1689 acetaminophen recipients versus 2422 non-recipients), propensity score matching resulted in 3124 matched subjects (1562 per cohort). The primary outcome was 90-day mortality, while secondary outcomes included mortality rates at 30, 60, 180, and 365 days. Survival analyses utilized Cox proportional hazards regression and Kaplan-Meier curves, supplemented by subgroup analyses for 90-day mortality.
resultsAcetaminophen exposure was correlated with reduced 30-day mortality rate (HR = 0.78, 95%CI [0.65-0.94], p < 0.05), as well as decreased 60-day (HR = 0.71, 95%CI [0.60-0.83], p < 0.001), 90-day (HR = 0.70, 95%CI [0.60-0.81], p < 0.001), 180-day (HR = 0.70, 95%CI [0.60-0.80], p < 0.001) and 365-day (HR = 0.69, 95%CI [0.61-0.79], p < 0.001) mortality rate after PSM. The Kaplan-Meier analysis demonstrated significantly higher survival rates in the acetaminophen group compared to the non-acetaminophen group, with a persistent trend at 30, 90, 180, and 365 days (log-rank p < 0.05). The protective effect was consistent across subgroups except acetaminophen dosage ≥ 650 mg.
conclusionEarly administration of acetaminophen is associated with reduced short- and long-term mortality in SAE patients. These findings support a potential therapeutic role for acetaminophen in SAE and warrant further mechanistic and prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.